Trial Information

OBJECTIVES: I. Assess the response of patients with adrenocortical carcinoma treated with
suramin. II. Evaluate the qualitative and quantitative toxic effects of this therapy.

OUTLINE: Patients are described according to stage, performance status, prior radiotherapy,
prior surgery, and prior mitotane therapy. Patients receive suramin IV for 5 days in the
first week, then twice a week for 2 weeks, and then weekly for a total of 12 weeks.
Hydrocortisone is taken PO twice daily. Following a 12 week rest, patients receive a second
course; those with stable or responding disease continue treatment for a maximum of four
courses.

PROJECTED ACCRUAL: A maximum of 40 patients will be accrued at a rate of 6-7 per year.

Inclusion Criteria

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Hematopoietic: WBC
at least 4,000/mm3 Absolute granulocyte count at least 2,000/mm3 Platelet count at least
150,000/mm3 Prothrombin time and partial thromboplastin time no greater than upper limit
of normal (ULN) Hepatic: SGOT and alkaline phosphatase no greater than 2 times ULN Renal:
Creatinine clearance at least 50 mL/min Serum creatinine no greater than ULN Other: No
second malignancy within 5 years except adequately treated basal cell or squamous cell
carcinoma of the skin,in situ carcinoma of the cervix, or other cancer for which patient
has been disease free for 5 years Not pregnant or nursing Effective contraception required
of fertile patients

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.